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ABSTRACT 
Objective: To establish if depression results in poor adherence to therapy in patients with heart diseases.  
Methods: This concept scoping study was conducted in two phases; the first was a systematic review of the literature, and the second part was local 
data analysis. Statistical analysis was performed using RevMan® V.5.3 (Cochrane Community).  
Results: Patients who received multidisciplinary collaborative care showed significantly reduced major adverse cardiac outcomes in patients with 
cardiovascular diseases. They also demonstrated higher rates of self-reported remission of depression. The review also showed endpoint mortality 
after PCI was associated with patients having depression. Local population data showed that 26% of heart failure patients had mental ill health 
comorbidity, however, only 12% had a formal diagnosis recorded.  
Conclusion: Depression is associated with poor cardiac outcomes in patients with coronary artery disease. It is widespread in patients with 
cardiovascular disease and must be screened for throughout the management plan. 
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INTRODUCTION 
Depression is widely reported to lead to adverse coronary heart 
disease (CHD) prognosis [1] poorer quality of life and increased 
healthcare costs [2]. The relationship has been widely examined and 
meta-analyses have demonstrated that depressive symptoms have 
an unfavorable impact on mortality and cardiovascular events in 
CHD or patients with post-MI [3]. 
Whilst there is much evidence of the link between these two 
conditions, previous pharmacological and psychological 
interventions explicitly implemented for this population have 
demonstrated lower levels of an effect than seen in other chronic 
diseases such as diabetes [4]. Furthermore, larger trials such as the 
Enhancing Recovery in CHD (ENRICHD) [5] study did not 
demonstrate a significant reduction in major adverse cardiac events; 
they concluded that the cognitive behavioural therapy intervention 
provided, improved depression and social isolation, though the 
relative improvement in the psychosocial intervention group 
compared with the usual medical care group was less than expected, 
due to substantial improvement in usual care patients [5]. This led to 
the studies being questioned and the authors stating that managing 
this patient group remains a challenge as there is no conclusion 
about the best intervention to achieve positive outcomes [6]. 
Recent works explain that collaborative care has provided 
encouraging models of healthcare in patients with depression and 
anxiety. These collaborative care models have been associated with 
significant improvement in depression and anxiety outcomes 
compared with usual care [7]. 
Collaborative care is defined by a multidisciplinary approach to 
patient care; this is typically coordinated by the patient’s General 
Medical Practitioner (GP) and another health professional, such as a 
counsellor. The process involves a structured patient management 
platform, with planned interventions, reviews and follow-ups, which 
include inter-professional communication between the different 
team members [8]. The number of viable RCTs that specifically 
assessed heart failure and depression is limited, and this review 
presents the available data, including broadened search terms [9]. 
The success of collaborative multidisciplinary care depends on the 
communication between healthcare professionals and their efforts 
to follow-up with patients on a regular basis.  
METHODS 
This study aims to explore if depression results in adverse outcomes in 
patients with coronary heart disease by review of the available data and 
to understand the current interventions employed to improve coronary 
heart disease prognosis with depression comorbidity. Also, to 
systematically review the evidence for the efficacy of multidisciplinary 
shared care approaches for depression in adults diagnosed with heart 
diseases. This concept scoping study was conducted in two phases; the 
systematic review and analysis of local data. 
Part 1: a critical review  
Review Manager (RevMan® V.5.3) (Cochrane community) was used 
for data assessment and analyses. Statistical analysis involved the 
assessment of the pooled data comparing collaborative 
multidisciplinary care and standard care. Also compared were 
patient outcomes in depressed and non-depressed individuals for 
the endpoint of adverse cardiovascular events. Dichotomous 
frequency data were extracted from the studies and the reported 
risk ratios (RR), standardized mean differences (SMD) for 
continuous variables and odds ratios (ORs) for dichotomous end-
points were reported with 95% Confidence Intervals (CI). Studies 
were compared based on the following aspects:  
Inclusion criteria: Prospective study design; coronary heart disease 
patient population with depression co-morbidity; patients 
diagnosed with coronary artery disease who had received coronary 
stent implantation; used established assessment inventories to 
define depression and reported depression end-point scores or 
major adverse cardiac events.  
Interventions: An RCT of multidisciplinary collaborative care, where 
patients received a structured management plan to deliver 
pharmacological or non-pharmacological interventions for 
depression and were followed up with inter-professional 
communications between members of a care team.  
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Control group: Patients receiving their usual care, or on the waiting 
list for treatment or no specific treatment for CHD and depression 
comorbidity.  
Primary outcome: Major adverse cardiac events e. g. heart failure 
exacerbation, myocardial infarction, all-cause and/or CHD-
related mortality or stroke or undergoing a revascularization 
procedure.  
Secondary outcomes: Standardised measures using self-reporting 
questionnaires of depression, anxiety, quality of life (QOL) and cost-
effectiveness, quality-adjusted life-years (QALY) and death. 
Search strategy 
The search strategy included keywords–coronary heart disease, 
heart failure and depression. Due to the lack of published RCTs on 
heart failure and depression; studies detailing CHD were also 
included to widen the search returns.  
Electronic databases were searched using the Cochrane Central 
Register of Controlled Trials (CENTRAL) on The Cochrane Library, 
MEDLINE, and EMBASE. The search yielded a small number of 
studies, as was found by Tully and Baumeister [9].  
The search results identified 10 studies that were suitable to review. 
However, only 6 studies were initially included as they had a similarity 
that can be compared and 4 were excluded due to their different 
endpoint.  
The 6 studies (table 1) [10-15] that were chosen covered a total of 
1284 patients with CHD and depression/anxiety comorbidity, where 
655 patients were randomized to the intervention group of 
collaborative care and 629 patients to control. For the purpose of 
studying the effect of collaborative multidisciplinary care on major 
adverse coronary outcomes, only 3 RCTs [11-12, 14] were included.  
For the purpose of assessing the effect collaborative 
multidisciplinary care has on depression remission outcomes, 5 
trials [11-15] met the inclusion criteria.  
For the purpose of assessing the effects of depression on patients 
after a percutaneous coronary intervention (PCI), only four studies 
(table 2) were included. 
  
Table 1: Randomised controlled trials reporting the difference between a collaborative acre and standard care (Direct qoutation) 
Study  Study design Length of 
intervention 






12 mo Planned review every 3 mo to the practice nurse and 
their primary care practitioner over a 12-month 
period. Patient received referrals to mental health 
services. 
Usual care; Practice 













8 mo Planned telephone reviews led by a nurse and 
supervised by psychiatrist and primary care 
practitioner. Including shared decision making for 
depression. Psychoeducation was provided by way of 
bibliotherapy. Medication initiation/alteration and 
promotion of adherence for antidepressant 
medication was provided by the primary care 
practitioner. Referral to the community mental health 
team if needed. A combination of the above; or 
watchful-waiting 
Usual care and 













6 mo Initial patient preference for problem-solving therapy 
by a problem-solving therapist (PST); treatment given 
via phone/internet and/or pharmacotherapy; or 
neither. Then a stepped-care approach every 6–8 w, 
with planned follow-up every week with PST, 
extended to longer intervals as needed 











6 mo Psychiatrist and social workers provide tailored 
treatment-patient preference for pharmacotherapy or 
CBT (minimum of 6 sessions). Review and provided 
stepped-care along with planned telephone calls and 
follow-up to monitor symptoms, promote adherence 
and patient engagement 
Enhanced usual 
care and primary 
care practitioner 
informed of 





and item about 






6 mo  Patient evaluated for preference for problem-solving 
therapy and/or pharmacotherapy; repeated 
assessments and a stepped-care approach if needed 
at 8 w intervals. Planned follow-up initially every 
week with PST or 1–2 and 3–5 w to titrate medication 






3 mo Psychiatrist and social worker providing patient 
centred depression treatment-based on history and 
patient preference e. g. pharmacological or 
psychotherapy. The study team advised the primary 
care practitioner and/or cardiologist with the 
treatment recommendations. Depression education 
and monitoring depression scores 
Usual care; PCP 
informed of 
depression status 
PHQ-2 and PHQ-9 
 
Systematic review findings  
The 6 RCTs that met the inclusion criteria to review the effects of 
collaborative care included 1284 patients with CHD with depression 
and anxiety comorbidities. Of these, a total of 655 patients were 
randomised to receive multidisciplinary collaborative care and 629 
patients were controls. A description of the included trials is shown 
in table 1. In table 2, all four studies were included in the Forest Plot 
to statistically review the effect that depression has on patients post 
PCI. All the trials were from outside the UK, although the mental 
health screening questionnaires were well known and varied only 
minimally, using the Patient Health Questionnaire (PHQ) [20], the 
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Beck Depression Inventory (BDI) [21], the Hospital Anxiety 
Depression Scale (HADS) [22], and the Mini-International 
Neuropsychiatric Interview (MINI) [23]. For studies assessing 
multidisciplinary collaborative care pathways, interventions were 
provided for from 3 to 12 mo, with the median duration being 6 mo. 
Interventions were delivered by nurses in the Bypassing the Blues 
and TrueBlue trials; allied healthcare teams in the COPES and 
CODIACS trials and by social workers in the MOSAIC and SUCCEED 
trials. Pharmacists were not involved with any of these 
interventions.  
Psychotherapy was delivered as part of the multidisciplinary 
collaborative care interventions and included problem-solving 
therapy in the COPES and the CODIACS studies, telephone-delivered 
CBT in the MOSAIC study and referral to community mental health 
services in the TrueBlue and Bypassing the Blues studies and a 
mixture of interventions in the SUCCEED study.  
Pharmacological interventions varied for each study and included 
selective serotonin reuptake inhibitors (SSRIs), bupropion and, 
serotonin and norepinephrine reuptake inhibitors (SNRIs). 
The risk of bias differed in each of the trials; each trial rated blinding 
to the subjective endpoints as high. However, on review of the study 
results, some studies employed selective reporting and other studies 
had uncertain allocation concealments. There was also missing trial 
information for some of the studies.  
Multidisciplinary collaborative care was also reported to reduce 
major adverse cardiac outcomes significantly (fig. 1). Such outcomes 
were only reported in the COPES, CODIACS and the Bypassing the 
Blues trials. However, these studies only demonstrated a reduction 
in cardiac events in short and medium timeframes (RR=0.54; 95% CI 
0.31 to 0.95 and p=0.03). No association was made with mortality 
rates (RR 1.38; 95% CI 0.53 to 3.58 and p=0.51). 
 
Table 2: Studies used in metaanalysis 
Reference  Screening tool used Conclusions 
[16] Hospital Anxiety and 
Depression Scale (HADS) 
Anxiety at baseline was associated with an increased 10-year mortality rate after PCI. Depression was 
also associated with higher 10-year mortality 
[17]  HADS The prevalence of depression and anxiety was 24.8% and 27.7%, respectively. The cumulative all-cause 
mortality rate in depressed patients was 37% versus 20% in non-depressed patients. Depression is 
associated with an increased risk of 77% for all-cause mortality, 10 y post-PCI, independently of anxiety. 
Although anxiety was associated with all-cause mortality, it has no additional value in the case of co-
occurring depression 
[18] HADS All-cause mortality rates differed significantly between depressed and non-depressed patients at 2-year 
follow-up, as 6 out of 98 subjects with elevated HADS-D scores (6.1 %), but only 8 out of 364 (2.2 %) 
patients with normal HADS-D scores had died [odds ratio = 2.9, 95 % confidence interval (95 % CI) = 1.0-
8.6, p = 0.044]. 
In CHD patients, self-rated depressive symptoms at baseline were negatively linked to survival at 2-year 
follow-up but failed to predict mortality 3 y later. Thus, in contrast to other well-established risk factors, 
the prognostic value of depression for predicting adverse outcome may be temporarily limited. The 




Patients with post-procedure depression had a higher rate of major adverse cardiac event (27.3 vs. 
13.0%, P<0.001), mortality (5.8 vs. 2.0%, P=0.044). post-procedure depression was seen to be an 
independent predictor of 3-year major adverse cardiac event 
 
 
Fig. 1: Comparison of major adverse cardiac events following multidisciplinary/collaborative care and usual care 
 
To evaluate whether depression in percutaneous coronary 
intervention (PCI) patients is associated with a higher risk of 
adverse outcomes was also examined.  
The four studies that are included in the Forest plot in fig. 3, demonstrate 
that endpoint mortality outcomes after PCI, are associated with a 
substantially higher risk of death in patients with depression (RR=1.43, 
95% CI 1.24 to 1.65). Overall, patients with depression demonstrated a 
significantly higher risk for the primary endpoint of a major adverse 
cardiac event, and for the secondary endpoint of death. 
With regards to the self-reported depression scores, in short timeframes, 
all the studies demonstrated an improvement in mood (fig. 2).  
Multidisciplinary collaborative care has shown to be considerably 
associated with depression remission (OR=1.77; 95% CI 1.28 to 
2.44, p=0.0005). However, only the COPES trial demonstrated 
ongoing depression responses at a medium length of time, using the 
Beck Depression Inventory (OR 2.26; 95% CI 1.14 to 4.46, p=0.02). 
Collectively, all depression remission data in the trials indicated 
similar results. 
In previous systematic reviews, it was found that antidepressant 
medication and psychotherapy yielded similar results of 
depression remission in patients with coronary heart disease 
[4]. 
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Fig. 2: Comparison: multidisciplinary (MD) collaborative care vs usual care, outcome: depression remission 
 
 
Fig. 3: Forest plot of depression and mortality endpoint as an outcome following PCI; Outcomes; Favour depression or favours no 
depression 
 
RESULTS AND DISCUSSION 
CONCLUSION 
Systematic Review Conclusion 
The 3 studies included in the analysis of the major adverse cardiac event 
in multidisciplinary collaborative care and usual care; COPES, CODIACS 
and Bypassing the Blues, demonstrated a reduction in major adverse 
cardiac outcomes in patients receiving multidisciplinary collaborative 
care. When reviewing patients’ post-PCI, studies demonstrated a 
significant reduction in major adverse cardiac events and death in 
patients with no depression compared to patients who were diagnosed 
with depression. The COPES, CODIACS, MOSAIC, SUCCEED, Bypassing 
the Blues and True-blue studies demonstrated short term positive 
outcomes in depression remission and an improvement in depression 
scores when patients received multidisciplinary collaborative care, 
compared to receiving usual care. In the UK, there is no consensus on the 
optimal inventory tool to screen for depression in patients diagnosed 
with coronary heart disease. 
Only one study utilised a clinical interview to diagnose depression in 
the form of the Mini-International Neuropsychiatric Interview 
(MINI) [23]. The remaining 9 studies utilised PHQ [20], BDI [21] and 
HADS [22] self-reporting tools. This meta-analysis demonstrates 
that depression is associated with poor cardiac outcomes in patients 
with coronary artery disease. Depression is widespread in patients 
with cardiovascular disease and must be screened for throughout 
the management plan to ensure that their mental health does not 
have an impact on their cardiovascular outcomes [24]. Systematic 
review of the available data, combined with statistical analysis, 
demonstrated that multidisciplinary collaborative care reduces major 
adverse cardiac outcomes significantly in patients with cardiovascular 
diseases (CVD). The review also revealed that end point mortality 
outcomes after PCI are associated with a substantially higher risk of 
death in patients with depression. With regards to the self-reported 
depression scores in short timeframes, all studies included in the 
review demonstrated an improvement in mood.  
Part 2-Comparison with local experience  
The local practice population consists of 6500 patients; of these, 50 
patients are included on the heart failure register. A total of 884 
patients have a diagnosis of depression.  
The table below details relevant treatment and diagnoses for all 
patients with heart failure at one medical practice in the United 
Kingdom (UK) (fig. 4). 
  
 
Fig. 4: Local practice heart failure patients population by age and gender 
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Fig. 5: Cardiovascular comorbidity in the local practice population 
 
 
Fig. 6: Local practice population medical conditions 
 
 
Fig. 7: Mental ill-health medications included in local practice heart failure population medication lists 
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Fig. 8: Most used medications in the local practice population 
 
From the 50 patients with heart failure, 6 patients have had a 
documented diagnosis of depression and/or anxiety. Out of all 
patients, there were 124 with documented cardiovascular 
conditions (fig. 5), with the most common comorbidities of diabetes 
and chronic obstructive pulmonary disease (COPD) (fig. 6). 
There were 16 prescriptions for medications used in the treatment 
of mental ill-health (fig. 7), but only 6 patients had a documented 
diagnosis. 
The most used medications (in 5 patients or more) were 
Simvastatin, ‘Biologics,’ Digoxin, Paracetamol, Omeprazole, Calcium 
and vitamin D, Ramipril, Aspirin, Furosemide, Atorvastatin, 
Bisoprolol, Inhalers (fig. 8). 
Local Audit Conclusion 
Based on the finding from the local population information, it was 
clear that while a high percentage of heart failure patients (26% of all 
patients) are prescribed medications for mental illness, only 12% of all 
patients had a documented diagnosis, which is lower than the general 
UK heart failure population (13%). This finding indicates that the 
national prevalence of mental illness in heart failure patients may be 
underestimating the actual problems in this population. It is 
recommended that primary care health professionals:  
• Medically review all patients diagnosed with heart failure for 
mental ill-health. 
• Use a standardised algorithm to assess for depression or anxiety. 
• Document any diagnoses on the PMR. 
• Follow-up patients with depression and anxiety in line with the 
clinical and local guidelines.  
• Clarify all diagnoses in patients receiving medications that could 
be used for depression and/or anxiety. 
• Ensure all patients receiving medication for mental ill health 
have the option of receiving psychotherapy.  
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